Evaluation of the effect of donepezil on cerebral blood flow velocity in Alzheimer's disease

Neurosciences

Volumn 15, Issue 3, 2010, Pages 172-176

  Ghorbani, Abbas ^a   Chitsaz, Ahmad ^a   Shishegar, Mehdi ^a   Akbari, Mojtaba ^b  

^a Department of Research ^*  (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; INDAN DERIVATIVE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD FLOW VELOCITY; BRAIN BLOOD FLOW; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; DIASTOLE; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; IRAN; MALE; MINI MENTAL STATE EXAMINATION; POSTERIOR CEREBRAL ARTERY; SYSTOLE; TREATMENT DURATION; ANALYSIS OF VARIANCE; BRAIN CIRCULATION; DRUG EFFECT; ECHOGRAPHY; EVALUATION; METHODOLOGY; MIDDLE AGED; MIDDLE CEREBRAL ARTERY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; BLOOD FLOW VELOCITY; CEREBROVASCULAR CIRCULATION; FEMALE; HUMANS; INDANS; IRAN; MALE; MIDDLE AGED; MIDDLE CEREBRAL ARTERY; NOOTROPIC AGENTS; PIPERIDINES; POSTERIOR CEREBRAL ARTERY; RETROSPECTIVE STUDIES; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 77957271888     PISSN: 13196138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Wilson RS, Aggarwal NT, Barnes LL, Mendes de Leon CF, Hebert LE, Evans DA. Cognitive decline in incident Alzheimer disease in a community population. Neurology 2010; 74: 951-955.
2. Moro ML, Collins MJ, Cappellini E. Alzheimer's disease and amyloid beta-peptide deposition in the brain: a matter of "aging"? Biochem Soc Trans 2010; 38: 539-544.
3. Muth K, Schönmeyer R, Matura S, Haenschel C, Schröder J, Pantel J. Mild cognitive impairment in the elderly is associated with volume loss of the cholinergic basal forebrain region. Biol Psychiatry 2010; 67: 588-591.
4. Tsuno N. Donepezil in the treatment of patients with Alzheimer's disease. Expert Rev Neurother 2009; 9: 591-598.
5. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004; 5: 347-360.
6. Thatcher GR, Bennett BM, Reynolds JN. NO chimeras as therapeutic agents in Alzheimer's disease. Curr Alzheimer Res 2006; 3: 237-245.
7. Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 2001; 64: 575-611.
8. Petrella JR, Coleman RE, Doraiswamy PM. Neuroimaging and early diagnosis of Alzheimer's disease: a look to the future. Radiology 2003; 226: 315-336.
9. Claassen JA, Jansen RW. Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: the cholinergic-vascular hypothesis. J Gerontol A Biol Sci Med Sci 2006; 61: 267-271.
10. Schaeffer EL, Gattaz WF. Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme. Psychopharmacology (Berl) 2008; 198: 1-27.
11. Hanyu H, Sato T, Hirao K, Kanetaka H, Iwamoto T, Koizumi K. The progression of cognitive deterioration and regional cerebral blood flow patterns in Alzheimer's disease: a longitudinal SPECT study. J Neurol Sci 2010; 290: 96-101.
12. Hamel E. Cholinergic modulation of the cortical micro vascular bed. Prog Brain Res 2004; 145: 171-178.
13. Park L, Anrather J, Forster C, Kazama K, Carlson GA, Iadecola C. Abeta-induced vascular oxidative stress and attenuation of functional hyperemia in mouse somatosensory cortex. J Cereb Blood Flow Metab 2004; 24: 334-342.
14. Pratt RD, Perdoma CA. Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits. Ann N Y Acad Sci 2002; 977: 513-522.
15. Rosengarten B, Aldinger C, Kaufmann A, Kaps M. Comparison of visually evoked peak systolic and end-diastolic blood flow velocity using a control system approach. Ultrasound Med Biol 2001; 27: 1499-1503.
16. Rosengarten B, Huwendiek O, Kaps M. Neurovascular coupling and cerebral autoregulation can be described in terms of a control system. Ultrasound Med Biol 2001; 27: 189-193.
17. Kohler CG, Martin EA, Kujawski E, Bilker W, Gur RE, Gur RC. No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia. Cogn Neuropsychiatry 2007; 12: 412-421.
18. Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer's disease. Neurology 2007; 69: 458-469.
19. Bassil N, Grossberg GT. Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. CNS Drugs 2009; 23: 293-307.
20. Sanchez CE, Schatz J, Roberts CW. Cerebral blood flow velocity and language functioning in pediatric sickle cell disease. J Int Neuropsychol Soc 2010; 16: 326-334. Epub 2010 Feb 3.
21. Rosengarten B, Kaps M. Peak systolic velocity Doppler index reflects most appropriately the dynamic time course of intact cerebral autoregulation. Cerebrovasc Dis 2002; 13: 230-234.
22. Rosengarten B, Paulsen S, Molnar S, Kaschel R, Gallhofer B, Kaps M. Acetylcholine esterase inhibitor donepezil improves dynamic cerebrovascular regulation in Alzheimer patients. J Neurol 2006; 253: 58-64.
23. Claassen JA, Jansen RW. Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: the cholinergic-vascular hypothesis. J Gerontol A Biol Sci Med Sci 2006; 61: 267-271. Review.
24. Lojkowska W, Ryglewicz D, Jedrzejczak T, Minc S, Jakubowska T, Jarosz H, et al. The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia. J Neurol Sci 2003; 216: 119-126.
25. Nakano S, Asada T, Matsuda H, Uno M, Takasaki M. Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J Nucl Med 2001; 42: 1441-1445.
26. Nobili F, Koulibaly M, Vitali P, Migneco O, Mariani G, Ebmeier K, et al. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. J Nucl Med 2002; 43: 983-990.
27. Kono I, Mori S, Nakajima K, Nakagawa M, Watanabe Y, Kizu O, et al. Do white matter changes have clinical significance in Alzheimer's disease? Gerontology 2004; 50: 242-246.
28. Gold G. Defining the neuropathological background of vascular and mixed dementia and comparison with magnetic resonance imaging findings. Front Neurol Neurosci 2009; 24: 86-94.